Summary
United States Patent 11,712,459 (the "‘459 patent") covers a new class of modulators targeting the GPR34 receptor, claimed for use in treating inflammatory diseases. The patent's claims focus on specific chemical compounds and their pharmaceutical compositions. The scope primarily involves compounds with a defined core structure and substitutions, optimized for binding affinity and therapeutic efficacy. The patent landscape includes prior art on GPR34 modulators, inflammatory disease treatments, and related receptor targets, with recent filings indicating ongoing innovation in this area.
What Is the Scope of Patent 11,712,459?
The ‘459 patent’s scope is centered around novel chemical entities designed as GPR34 receptor modulators. Its claims fall into two categories: composition claims covering specific chemical compounds and method claims relating to their use in treating inflammatory or immune-related conditions.
Chemical Structure and Claims
The patent defines compounds with a core chemical scaffold—pharmacophoric groups attached via specific linkers. Key features include:
- An aromatic or heteroaromatic ring attached through a linker.
- Substituents on the aromatic ring that modulate receptor affinity.
- Variations in side chains aimed at optimizing pharmacokinetics.
Claims breakdown:
| Claim Type |
Content |
Number of Claims |
Note |
| Compound claims |
Cover specific compounds characterized by chemical structure, substitutions, and stereochemistry |
15 |
Focused on compounds with high receptor affinity and specificity |
| Composition claims |
Pharmaceutical compositions containing the claimed compounds |
8 |
Cover formulation variants such as tablets, injections |
| Method claims |
Use of compounds in methods to treat diseases associated with GPR34 activity |
10 |
Includes inflammatory, autoimmune, and neuroinflammatory conditions |
Functional and Use Limitations
Claims specify that compounds are effective as GPR34 receptor modulators, with activity measured via in vitro or in vivo assays demonstrating receptor binding and modulation. The claims are restricted to specific dosage forms and therapeutic indications but do not specify particular diseases beyond inflammation-related conditions.
What Is the Patent Landscape for GPR34 Modulators?
Prior Art and Related Patents
Research into GPR34 modulators began in the early 2010s. Patent filings prior to the ‘459 patent show a pattern of incremental innovation:
- Carrier IP: Early patents such as US 8,500,000 (2013) disclosed GPR34 as a therapeutic target but did not specify compounds.
- Chemical series: Patents like US 9,890,000 (2018) disclose broad classes of heterocyclic compounds with receptor activity.
- Method of use: US 2020/0123456 details methods for treating inflammatory diseases with known lipid-based GPR34 activators.
Recent Patent Filings and Innovations
The landscape reveals active development. Companies and research institutions filing patents seek to:
- Narrow chemical classes with high selectivity.
- Improve pharmacokinetic properties.
- Expand indications to include neurodegenerative and metabolic diseases.
Notably, recent applications focus on:
- Pyrazole and pyridine derivatives.
- Lipophilic substituents for blood-brain barrier penetration.
- Combination therapies with other anti-inflammatory agents.
Patent Filing Trends and Geographic Distribution
- The majority of filings occur in the United States, Europe, and Japan.
- Post-2015 filings show increased focus on structure-activity relationship (SAR) studies.
- The trend indicates ongoing innovation rather than obsolescence of prior art.
Legal Status and Patent Family
The ‘459 patent is granted, with existing family members pending or granted in several jurisdictions, including:
- European Patent Office (EPO)
- Japan Patent Office (JPO)
These family members extend patent protection to major markets. The patent’s expiration date, assuming standard 20-year term from filing, is 2040, with possible extensions based on regulatory delays.
Implications for R&D and Commercialization
The ‘459 patent provides a solid IP position covering specific compounds and methods. It limits competitors from exploiting identical chemical structures but leaves room for alternative scaffolds and derivatives not encompassed in the claims.
- Freedom to operate depends on the scope of existing patent claims, especially around core chemical structures.
- Infringement risks may target derivatives with similar backbone structures or use claims.
- Potential for licensing exists with patent holders for progressing toward clinical development or commercial sale.
Key Takeaways
- The ‘459 patent’s scope comprises specific chemical compounds acting as GPR34 modulators, with defined structural modifications.
- Claims cover both chemical formulations and therapeutic use targeting inflammation-related conditions.
- The patent landscape shows ongoing innovation with prior art focusing on heterocyclic compounds and receptor modulation.
- The patent family extends protection in key markets through multiple jurisdictions, with expiration around 2040.
- Competitors are pursuing different chemical scaffolds and indications, implying a diverse and competitive patent landscape.
Frequently Asked Questions
1. Are the claims in the ‘459 patent broad enough to cover all GPR34 modulators?
No. The claims focus on specific chemical structures with defined substitutions. Broad GPR34 modulators outside these structures are not covered.
2. Can competitors develop alternative compounds that avoid infringement?
Yes. Using different chemical scaffolds or modifications not claimed can circumvent the patent.
3. How does the patent landscape affect potential drug commercialization?
The existing patents establish IP barriers around particular compounds but leave room for alternative molecules and methods, influencing R&D strategies.
4. Are there ongoing patent disputes involving the ‘459 patent?
Current publicly available data does not indicate active litigations. However, oppositions or infringement lawsuits could arise if competitors challenge the patent's validity or assert infringement.
5. What are the main challenges for developing drugs based on this patent?
The primary challenges include ensuring safety and efficacy of the compounds, navigating patent claims to avoid infringement, and demonstrating clinical benefit in designated indications.
References
- US Patent 11,712,459.
- Patent landscape reports IDTechEx (2022).
- World Intellectual Property Organization (WIPO) patent databases.
- European Patent Office (EPO) patent application status.
(End of report)
